<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014573</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068559</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-D-1654</secondary_id>
    <secondary_id>WSU-07-92-98-P04-FB</secondary_id>
    <secondary_id>NCI-G01-1937</secondary_id>
    <nct_id>NCT00014573</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer</brief_title>
  <official_title>Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell&#xD;
      transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more&#xD;
      tumor cells. Vaccines made from a person's white blood cells and tumor cells may make the&#xD;
      body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's&#xD;
      white blood cells to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and vaccine&#xD;
      therapy followed by bone marrow or peripheral stem cell transplantation and interleukin-2 in&#xD;
      treating patients who have recurrent or refractory brain cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the effectiveness of induction paclitaxel and cyclophosphamide followed by&#xD;
           autologous tumor cell vaccine and sargramostim (GM-CSF) followed by high-dose&#xD;
           chemotherapy with cisplatin, cyclophosphamide, and carmustine, autologous bone marrow or&#xD;
           peripheral blood stem cell transplantation, and interleukin-2 in patients with recurrent&#xD;
           or refractory primary high-grade brain tumors.&#xD;
&#xD;
        -  Determine the safety and toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine if a specific quantitative cellular response can be elicited in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: After partial surgical resection of tumor, patients receive induction chemotherapy&#xD;
      comprising paclitaxel IV over 3 hours and cyclophosphamide IV over 1 hour on day 1. Patients&#xD;
      also receive filgrastim (G-CSF) subcutaneously (SC) daily beginning on day 3 and continuing&#xD;
      until peripheral blood stem cell (PBSC) or bone marrow collection is completed.&#xD;
&#xD;
      After the collection of PBSC or bone marrow, patients receive autologous tumor cell vaccine&#xD;
      and sargramostim (GM-CSF) SC once every 2 weeks for up to 5 vaccinations. Two weeks after the&#xD;
      last vaccination, patients undergo a second leukapheresis to collect lymphocytes.&#xD;
&#xD;
      After completion of the second leukapheresis, patients receive high-dose chemotherapy&#xD;
      comprising cisplatin IV continuously over 24 hours on day -5, cyclophosphamide IV over 1 hour&#xD;
      on days -5, -4, and -3, and carmustine IV over 2 hours on day -2. Patients undergo autologous&#xD;
      bone marrow or PBSC transplantation on day 0. Patients receive G-CSF IV daily beginning on&#xD;
      day 0 and continuing until blood counts recover.&#xD;
&#xD;
      Approximately 12 weeks after bone marrow or PBSC transplantation, patients receive autologous&#xD;
      lymphocytes IV over 2-5 hours. Patients also receive interleukin-2 IV once every other day&#xD;
      for 10 days.&#xD;
&#xD;
      Patients are followed at 18, 24, 36, 40, and 52 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1998</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous tumor cell vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed active recurrent or refractory primary high-grade brain tumor&#xD;
&#xD;
               -  Tumor must be surgically accessible&#xD;
&#xD;
          -  Bidimensionally measurable disease by clinical exam, CT scan, or x-ray&#xD;
&#xD;
               -  Disease must be outside a previously irradiated field or have progressed or&#xD;
                  developed after radiotherapy&#xD;
&#xD;
               -  Previously treated metastatic bony lesions are not considered measurable&#xD;
&#xD;
               -  No previously irradiated metastatic disease site unless no response or clear&#xD;
                  progression on imaging&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  65 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  CALGB 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Liver function less than 2.5 times normal unless due to disease&#xD;
&#xD;
          -  No active hepatitis B or C&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Left ventricular ejection fraction greater than 50% by MUGA or 2-D echocardiogram&#xD;
&#xD;
          -  Electrocardiogram normal&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV1 and DLCO greater than 50% predicted OR&#xD;
&#xD;
          -  Clearance by pulmonologist&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No serious underlying co-morbid disease or other medical or psychiatric factor that&#xD;
             would preclude study&#xD;
&#xD;
          -  Able to be weaned off steroids after surgery&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Recovered from prior conventional chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent steroid therapy for mass effect&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior conventional radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esteban Abella, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>April 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2004</study_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>adult choroid plexus tumor</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>adult grade III meningioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

